(NASDAQ: TEM, “Tempus”) today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”), under which BMS ...
Tempus to build a de-identified dataset from hundreds of thousands of patients with neurological conditions; Pathos to ...
Once an afterthought, air barriers are now essential in ensuring energy efficiency, moisture management, and occupant comfort ...
The disruption of sleeping and waking patterns from the daylight saving clock change reveals a great deal about our everyday ...
Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...
Pharmaceutical Technology on MSN
US targets Chinese biotech investment, but licensing deals remain exempt
Numerous types of equity deals, including the popular NewCo model, will be impacted by the proposed rule.
BioNTech enters a clinical trial collaboration with Gilead Sciences with the aim of improving outcomes in patients with PD-L1 low or negative ...
Plus, when to see a doctor about your BM schedule shifts.
Battery Technology & Industry Insights. As global demand for alternative battery technologies continues to grow, sodium-ion ...
Building on more than four decades of lead-acid expertise, Camel has developed lead-acid batteries for LEVs across 6V, 8V and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results